Received Jun 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | J4K4X | — |
an adult patient received a pediatric dose of Havrix; an adult patient received a pediatric dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 33-year-old female patient who received HAV (Havrix pediatric) suspension for injection in pre-filled syringe (batch number J4K4X) for prophylaxis. On 16-JUN-2026, the patient received Havrix pediatric. On 16-JUN-2026, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: an adult patient received a pediatric dose of Havrix) and underdose (Verbatim: an adult patient received a pediatric dose of Havrix). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.